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Abstract 
Recent advances in whole transcriptome sequencing have revealed that the majority of the 
genome is transcribed but only 1% of transcripts are coded for protein biosynthesis. This 
remaining ‘junk DNA’ includes non-coding RNA species (ncRNA), which have been implicated 
in modulating tumorigenesis as well as tumor suppression if they are misexpressed. Recent 
experiments indicate that loss of the Retinoblastoma tumor suppressor protein (pRB), a 
transcriptional co-regulator, alters the expression of both coding and non-coding transcripts. This 
project seeks to understand if misexpression of these ncRNAs plays a role in the pleiotropic 
effects of pRB loss in cancer. 
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Introduction & Background 
Overview of Retinoblastoma Protein (pRB) Pathway and Human Cancers 
The Retinoblastoma protein (pRB) is 
a central transcriptional regulator of 
cell proliferation and cell cycle 
progression. pRB was first identified 
as a gene that was associated with 
pediatric eye tumorigenesis, or 
Retinoblastoma over 25 years ago 
(Nevins, 2001; Dick & Rubin, 2013; 
Elchuri et al., 2018). Additionally, a 
great body of research has implicated 
deregulation of pRB’s function in 
uncontrolled cell cycle progression, 
as well as tumorigenesis of many 
human cancers (Dyson, 2016; Nevins, 2001). Thus, it is important to consider how pRB mediates 
mitosis. pRB’s function can be categorized as a negative regulator of the cell cycle (Dick & 
Rubin, 2013). The function and regulation of pRB is more complex however, as it involves the 
activity of numerous stimuli which act as pRB function regulators (Dick & Rubin, 2013; Peurala 
et al., 2013). Normally or in the absence of extracellular signals pRB is bound to E2F (as seen in 
Figure 1) preventing the transcription of genes needed for DNA replication; this inhibition of 
E2F transcription is why pRB is often referred as a tumor suppressor as this action prevents 
unscheduled entry of cells into the cell cycle by inducing G1 phase cell-cycle arrest (Dick & 
Rubin, 2013; Knudsen & Knudsen, 2008). When appropriate mitogenic conditions are met such 
 
Figure 1: pRB is a central transcriptional regulator of 
cell proliferation and cell cycle progression. Regulation of 
the cell cycle G1/S transition by cyclin D1, CDK4 and p16. 
RB, retinoblastoma protein, CDK4/6, cyclin-dependent 
kinase 4/6.Textbook model of pRB pathway. When pRB is 
bound to E2F transcription is repressed. Once pRB is 
phosphorylated, E2F is free to bind to genomic DNA to 
allow for the transcription of a given gene. 
Retrieved from: Peurala, E., Koivunen, P., Haapasaari, K., Bloigu, R., & Jukkola-
Vuorinen, A. (2013). The prognostic significance and value of cyclin D1, CDK4 
and p16 in human breast cancer. Breast Cancer Research: BCR, 15(1), R5–R5.. 
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as growth stimulation, pRB is phosphorylated through the activity of cyclin D1 and its partner 
CDK4/6 kinases (Dick & Rubin, 
2013; Nevins, 2001; Knudsen & 
Knudsen, 2008; Weinberg, 1995). 
At this point, p16 referred to as 
p16INK4A, an inhibitor of CDKs 
aids in maintaining pRB’s 
phosphorylated state by inhibiting 
the activity of CDK4/6 (Peurala et 
al., 2013). Phosphorylated pRB 
detaches from the E2F allowing 
for gene transcription and cell 
cycle progression.   
Many cancers devise 
mechanisms to impair pRB 
function by mutating the RB gene 
or altering the expression of RB 
regulators (Figure 1) such as cyclin D, CDK 4 and 6 and p16 which inhibits them (Dick & 
Rubin, 2013). One can assume that a disruption in this pathway may result tumorigeneses 
(Weinberg, 1995). These species are all involved in what is referred to as the p16-cyclin-
CDK4/6-pRB pathway, which is compromised in many human cancers such as breast cancer 
(Peurala et al., 2013; Weinberg, 1995; Dyson, 2016; Nevin 2001). As illustrated in Figure 2, 
there is variation in how the pRB pathway is altered in a given the specific cancer phenotype. For 
 
Figure 2: pRB pathway heterogeneity in primary tumors. 
Consensus percentages reflective of numerous studies. Not 
assessed or indeterminate refers to research where a consensus 
has yet to be reached. ND refers to non-determined. SCLC and 
NSCLC refer to small and non-small cell lung cancer.  
Adapted from: Knudsen, Erik S., and Karen E. Knudsen. "Tailoring to RB: tumour 
suppressor status and therapeutic response." Nature Reviews Cancer, vol. 8, no. 9, 2008, p. 
714+.  
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example, the researchers Peurala et al. (2013) found that overexpression of cyclin D1 is 
correlated with a lower grade of tumor and thus a more favorable prognosis.  
In other cancers such as small lung cancers, retinoblastomas and bladder cancers pRB is 
known to be lost (Horowitz et al., 1990; Weinberg, 1995). p16 loss is another common feature in 
lung cancers has been studied as a biomarker for this cancer type (Weinberg, 1995; Tong et al., 
2011). This is in part, due to normally high levels of p16 found via immunohistochemistry 
approaches in lung tissue which reach near undetectable levels in lung carcinomas (Tong et al., 
2011).  
The various changes that have been discussed all affect the function of pRB and as a 
direct consequence, E2F is free to cause an uncontrolled proliferation of cellular proliferation, 
which is one of the many factors that results in tumorigenesis (Nevin, 2001). Thus, pRB plays a 
fundamental role in preventing oncogenic growth (Elchuri et al., 2018). Prior research, however, 
has shown that the loss or inactivation of pRB has more complex effects in response to cancer 
therapeutics specifically and may be a metric or avenue for the development of therapies 
(Knudsen & Knudsen, 2008).   
Additionally, recent microarray data as well as the advent of unbiased RNA sequencing 
(which measures all the RNA in a cell) has aided in whole transcriptome analysis and identified 
several genomic aberrations Retinoblastoma tumors such as non-coding RNAs, pseudogenes as 
well as RNA fusions which are characterized by altered RNA processing events (Elchuri et al., 
2018).  
Overview of Non-coding RNAs  
As potential altered transcripts in response to pRB loss for example, is important to 
understand and their significance as it pertains to cancer. Recent advances in transcriptome 
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sequencing has revealed that ~70-90% of the transcripts are expressed, but only 1% is 
responsible for coding proteins. This genomic dark matter is transcribed and yet it’s functions 
remain uncertain (Lee, 2012; Romano et al., 2017 ). What was originally thought as ‘junk-DNA,’ 
has now been shown to include noncoding species such as pseudogenes, intronic sequences, 
repeat sequences and most prominently noncoding RNA elements (Romano et al., 2017). These 
have been sorted by size, with transcripts longer than 200 nucleotides being referred to long non-
coding RNAs (lncRNAs) and shorter transcripts are referred to as short-interfering and 
microRNAs (siRNAs & miRNAs) (Zhuang et al., 2016; Romano et al., 2017). While ncRNAs 
such as tRNAs and rRNAs function has been clearly categorized, recent research has focused on 
the regulatory roles of ncRNA (Romano et al., 2017). Many noncoding sequences of RNA play 
regulatory roles in various contexts and can influence the epigenetic, transcriptional, and post-
transcriptional regulation of genes (Kruer et al, 2016; Romano et al., 2017).  As illustrated in 
Figure 3, these functional outcomes are a result of interactions with: 1) DNA, as lncRNA can 
alter chromatin structure and thus affect gene expression, 2) protein, as lncRNA can form 
protein-protein complexes that hinder or promote protein-protein interactions and 3) RNA, as 
ncRNA can affect mRNA decay and regulate expression of certain mRNA species (Schmitt & 
Chang, 2016; Romano et al., 2017). ncRNAs have also been implicated in modulating 
tumorigenesis and tumor suppression (Schmitt & Chang, 2016; Huarte, 2015; Wang et al., 2016). 
Misregulation of ncRNAs is associated with a poor prognosis and this dysregulated expression 
can be used as a biomarker for disease progression (Romano et al., 2017; Schmitt & Chang, 
2016; Huarte, 2015). Certain ncRNAs are involved in tumor suppression circuits involving pRB, 
such as the lncRNA MEG3 (Kruer et al, 2016; Schmitt & Chang).  
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Non-coding RNAs and pRB 
 In some human cancers such as Retinoblastoma, the loss of pRB is one of the nascent 
events that leads to tumorigenesis (Elchuri et al., 2018; Nevin 2001). And as discussed earlier, it 
is known pRB acts as a transcriptional regulator of the E2F family of transcription factors which 
are involved in the transcription of certain genes, but very little is understood about how this 
complex influences the expression of non-coding RNAs (Nevins, 2001; Dick & Rubin, 2013; 
Elchuri et al., 2018). Some labs armed with microarray data have attempted to understand the 
transcriptional changes in RB deficient sample and normal retinal pigment control cells (Zhang 
et al., 2012). There is also evidence of more direct influence of E2F binding in genomic loci of 
some non-coding RNAs which was determined via chromatin immunoprecipitation or ChIP 
experiments (Xu et al., 2007). These initial experiments provide hints at the potential of E2F and 
RB as potential transcriptional regulators of non-coding RNAs. 
Recently the Manning lab has produced preliminary some RNA sequencing datasets (as 
seen in Figure 4). These data were produced in non-transformed human epithelial cell line 
known as Retinal pigment Epithelium (RPE-1) where pRB was knocked-out (KO) via siRNA 
approaches. This RNA sequencing 
produced over 4000 misregulated 
transcripts which include protein-coding, 
non-coding and pseudogenes. Of these 
about 200 ncRNA are differentially and 
significantly upregulated in RPE-1 
following pRB K), and ~50 non-coding 
RNA were very significantly upregulated. 
 
Figure 3: ncRNA interactions with 
macromolecules.  
ncRNA interactions are dependent on interactions 
with macromolecule interactions. 
Retrieved from: Schmitt, Adam M., and Howard Y. Chang (2016). “Long 
Noncoding RNAs in Cancer Pathways.” Cancer cell 29.4 (2016): 452–
463. PMC. Web. 13 Oct. 2018. 
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Some of these upregulated non-
coding RNAs have intriguing 
roles as it pertains to 
tumorigenesis (purple dots in 
Figure 4). One such ncRNA is 
long intergenic non-coding RNA 
or LINC00342 which has been 
implicated as a potential 
biomarker for patients who have 
non-small lung cancer or 
NSLSC, the most prevalent type 
of lung cancer and involved in 
the most deaths (Tang et al., 
2019). The researchers Tang et 
al. (2019) studied serum, and 
tumor tissue samples of NSCLC 
patients and found evidence for 
LINC00342 as a biomarker for this cancer, as its higher expression of it is associated with a poor 
prognosis. Interestingly they also found that this overexpression promotes uncontrolled cell 
proliferation, a phenotype shared by many human cancers, by inhibiting p53 and PTEN which 
are proteins involved in cellular proliferation (Tang et al., 2019; Dick & Rubin, 2013). Other 
ncRNAs that were identified in this screen include brain derived neurotrophic factor antisense or 
BDNF-AS which had striking functional relevance to cancer (de Farias et al, 2012; Shang et al., 
 
Figure 4: A volcano plot representation of differentially 
expressed coding and non-coding transcripts following knockout 
of pRB. The log Fold Change of the gene expression levels observed 
following siRNA-based knockout of pRB is reported on the X axis, 
while the –log 10 of the p-value of the statistical test of differential 
expression (t-test) is shown on the Y axis. The RNAseq presented 3906 
genes that were misregulated following KO of pRB. And it produced 
200 coding, noncoding and pseudogenes that were significantly 
upregulated (p-value <0.01) and had fold change value >1. Of those 
200, a total of 50 noncoding genes were significantly upregulated (p-
value <0.01) and had log fold changes >1. Additionally, 30 ncRNA 
were significantly upregulated (p-value <0.001) and had log fold change 
values >1. The horizontal red line represents a statistical difference 
threshold of 0.01 for the p-value. The dashed horizontal line represents a 
statistical difference threshold of 0.001 for the p-value. Non-coding 
RNAs that had p-values were greater than the threshold of 0.001 were 
biologically misregulated and were of interest were labeled with purple 
dots. 
 
***
UpregulatedDownregulated
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2018). Previous research has 
shown that BDNF-AS is a 
inverse regulator of the coding 
transcript BDNF, thus has 
profound effects on neuronal 
development (Shang et al., 
2018). The researchers de Farias 
(2012) found that when 
colorectal tumor samples were 
exposed to anti-cancer drugs that affect proliferation by blocking growth factors, was 
compromised following the addition of BDNF-AS. This implies that BDNF-AS has some role in 
the proliferation of cells and tumorigenesis. Recently the efficacy of BDNF-AS as a biomarker 
for human cancer was assessed, and in Retinoblastoma tumor (RB) samples as well as RB cell 
lines a high level of BDNF-AS were present (Shang et al., 2018). Most strikingly, when BDNF-
AS was overexpressed in RB tumor cell line, these cells exhibited was lower motility and 
proliferation, than compared to control RB tumor cells in transwell migration assay as illustrated 
in Figure 5. 
Objective & Hypothesis 
 Previous research has shown that certain ncRNAs are dysregulated during tumorigenesis. 
This project will employ RNA sequencing data that the Manning Lab generated using a non-
transformed human epithelial cell line known as Retinal pigment Epithelium (RPE-1) and cells 
that are genetically identical but have been depleted of the pRB protein via siRNA. The aim is to 
explore which ncRNAs are misexpressed and are either upregulated or downregulated in 
 
Figure 5: Effect of BDNF-AS upregulation on RB cell 
proliferation and migration. A transwell migration assay 
performed on WERI-Rb-1 cells. Migrating RB cells in lower 
chambers were visualized through staining of crystal violet 
(left, scale bar: 20 μM). Relative migration capability was 
compared between Control RB cells and cells with BDNF-AS 
upregulation (right, *P < 0.05).  
Retrieved from: Shang, W., Yang, Y., Zhang, J., & Wu, Q. (2018). Long noncoding 
RNA BDNF-AS is a potential biomarker and regulates cancer development in human 
retinoblastoma. Biochemical and Biophysical Research Communications, 497(4), 1142–
1148.  
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response to pRB loss. Additionally, the functional relevance of these changes will be 
investigated to elucidate the mechanisms mediating the relationship between ncRNAs and cancer 
cell phenotypes that result from loss of pRB function. We hypothesize that some of the cellular 
changes that result from pRB loss are due to changes in ncRNA. 
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Results 
Verifying Biological Significance and Trends of Misregulated Non-coding RNA 
Previous literature has suggested the link between loss of pRB and misexpression of 
genes including non-coding RNAs (Nevins, 2001; Zhang et al., 2012; Dick & Rubin, 2013; 
Elchuri et al., 2018). Armed with this knowledge the results of the RNA screen (as seen in Figure 
4) I first set to verify the biological upregulation of candidate ncRNA transcripts presented in 
Table 1 that had been implicated in cancer biology studied. I worked with non-transformed RPE-
1 cells which were made to be pRB deficient via knockdown by a drug inducible short hairpin to 
disrupt pRB stability. This experiment was done in quadruplet, and each time 2 plates were 
prepared using the protocol above. Throughout each replicate, one of the plates was treated with 
2ug/mL of Doxycycline for 48 hours to induce knockdown. Quantitative PCR analysis indicated 
that this approach was sufficient to reduce pRB protein levels to approximately 30% of that seen 
in control cells. With this degree of pRB depletion, I was unable to confirm upregulation of most 
 
Table 1: Summary of misexpressed ncRNA and proposed function. 
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ncRNAs that were significantly upregulated in the RNAseq data set and found Kirrel-AS2 and 
XIST to be significantly downregulated, which in contrast to the results of our RNAseq screen 
A) 
 
B) 
 
 
Figure 6: Loss of pRB causes altered expression of ncRNA. qPCR analysis of candidate ncRNA 
expression and compared to the control group, relative fold changes were presented as mean ± SD. A) Red 
represents shRB knockdown of pRB. Blue represents control cells. Kirrel-AS2 and XIST have significantly 
higher fold expression.  B) Red represents siRNA knockout of pRB. Blue represents siScr which is our 
control. ASAP-IT1, LOC340113 and LINC00342 have significantly higher fold expression. (*) denotes P 
value < 0.05. 
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(Figure 4; Figure 6A). As a complementary approach I also assessed ncRNA levels in control 
cells and those depleted of pRB using siRNA based depletion mechanisms. Consistent with the 
RNAseq analysis (Figure 4), this approach resulted in a near complete depletion of pRB mRNA 
(< x%) and  led to the upregulation of several ncRNA transcripts, including ASAP-IT1, 
LOC340113 and LINC00342 (Figure 6B).  
 
 
 
 
Figure 7: ncRNAs both lack and contain E2F-1 consensus sequences. The MotifMap: genome-wide maps 
of regulatory elements tool was used to determine E2F’s binding sequence logo. A) Motif #1 relates to a E2F 
consensus sequence (HNTTTCHN) and B) Motif #2 corresponds to a E2F consensus binding sequence 
(VRAAAHST). DTU Promoter 2.0 Prediction Server was used to predict transcription start sites (TSS) of the 
ncRNA. Once the TSS was determined Broad Institute’s Integrated Genomic Viewer Software’s Motif Finder 
tool was used. C) Hits generated from Motif Finder Tool once the consensus sequences (A) and (B) were 
inputted. 
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Determining Putative E2F Binding Sequences on Candidate NcRNAs 
 In order to understand how these ncRNA’s may be upregulated some initial work by the 
researchers Xue et al. (2007) was referred to. Their work provided hints of potential binding of 
E2F near the genomic loci of ncRNAs. The researchers proposed a potential transcriptional 
regulatory role of pRB and E2F on the expression of ncRNAs due to the output of their ChIP 
experiments (Xue et al., 2007). If pRB is compromised E2F is free to bind to genomic DNA and 
potentially upregulate and misexpress candidate ncRNAs for example (Nevin, 2001). Based on 
this idea, a number of free online tools and software were utilized to determine binding of E2F 
upstream of the transcription start site of the candidate ncRNA. Using sequences previously 
determined to be recognition sequences for E2F1 binding (Figure 7A and 7B), alignment 
software was used to determine potential E2F regulatory sequences on each ncRNA of interest. 
(Figure 7C). Potential E2F1 binding sites were identified upstream of five of the nine ncRNAs 
assessed (Figure 7C), suggesting that in some cases ncRNA upregulation following pRB loss 
represents direct regulation by E2F. The absence of E2F1 consensus sequence on other ncRNAs 
suggest pRB may also regulate ncRNA transcripts in an E2F1-independent manner. 
 
Functional Outcomes of pRB Loss 
 To determine the functional relevance of loss of pRB-dependent ncRNA regulation, I 
explored the role of pRB in cell motility. Previous work had demonstrated the retinoblastoma 
cancer cells exhibit increased moitility Shang et al. (2018) but fell short of demonstrating that 
this change resulted from pRB loss and not from other changes in the cancer cells. Using movies 
generated by a previous student in the Manning lab, I sought to test the hypothesis that loss of 
pRB alone is sufficient to alter cell motility.  Using an hTERT RPE-1 cell line that was 
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engineered to express an RFP-tagged histone 2B (H2B) to enable visualization of nuclei, cells 
were maintained at 37C and 5%CO2 while microscopic images were captured every 5 minutes 
for up to 36 hours. Using Cell Profiler software suite, I assessed the motility of control and pRB-
depleted cells that were imaged as described above. A total of 100 cells that could be tracked for 
at least 12 frames or 1 hour were tracked in each condition were analyzed for their motility. I 
created a custom pipeline based on a template cell tracking pipeline produced by CellProfiler to 
assess the motility of the cells. This analysis made use of two powerful object processing 
modules: 1) ‘IdentifyPrimaryObjects’ and 2) ‘TrackObjects’. Briefly, the RPE-1 control and 
siRB cells first had to be recognized by the software so that they could then be identified be 
identified and their xy coordinates determined for each time coordinate.  From these xy 
coordinates, over time, cell velocity and total distance traveled could be calculated. These data 
aided in determining the displacement of these cells between frames using CellProfiler. 
Parameters used in optimizing these pipelines to efficiently identify and tract single cell nuclei 
can be found in the methods section. 
First, I assessed cell motility of cells that were plated at low density and remained sub-
confluent throughout the duration of the movie (<2.5h) (Figures 8A-C). When the average 
distance travelled by a single cell in a single frame (1 frame lasting 5 minutes) was assessed, 
pRB depleted RPE-1 cells were found to have a greater motility than control cells (Figure 8A). 
Additionally, when average displacement in the length of tracking was compared, siRB cells 
exhibited a significantly increased distance traveled than control cells (p<0.05; Figure 8B). Next, 
I assessed cell velocity and distance traveled of control and pRB-depleted in contact-inhibited 
populations of cells (imaged until confluency at 16.5-hour) (Figures D-F). As expected, control 
cells that experienced contact inhibition exhibited both decreased velocity and decreased 
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distance traveled. Interesting the pRB depleted RPE-1 cells maintain high motility as was seen in 
the assay performed at lower confluency.   
A)  B)  C)  
 
D) E) F)  
Figure 8: pRB deficient cells have altered motility. This experiment employed RPE-1 cells in which pRB was 
KO via siRNA, and control epithelial cells. Both of these cells were treated with a Histone 2 fluorescent label 
which aided in visualizing chromatin and nuclei of the cells. A) Distribution of low confluency wells 2 and 3, 
average distance traveled by individual cells in a 5 minute period or 1 frame, B) Average distance travelled in 
lifetime (29 frames) of all cells in a given well, C) Representative images of control epithelial cells at time 
minimum (frame 1; top) and maximum time point (frame 29; bottom). D) Distribution of high confluency wells 1 
and 4, average distance traveled by individual cells in a 5 minute period or 1 frame, E) Average distance travelled 
in lifetime (200 frames) of all cells in a given well, F) Representative images of control epithelial cells at time 
minimum (frame 1; top) and maximum time point (frame 200; bottom). 
*
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Conclusions & Future Directions 
Candidate NcRNAs May Be Regulated by Direct Binding of E2F 
 The data above highlights the downstream effects of pRB loss in terms of misexpression 
of candidate ncRNAs as well as phenotypic outcomes following knockout of pRB. One of the 
main aims of this project was to explore the role of the pRB-E2F complex as a potential 
transcriptional regulator of the candidate ncRNAs. Results have shown that ncRNAs both lack 
and contain putative E2F-1 binding sites (Figure 7). This is suggestive of direct regulation by the 
pRB pathway on the expression of ncRNA. Further experiments could be performed to verify the 
existence of these E2F-binding sites. 
Common transcriptional gene expression reporter assays such as a luciferase reporter 
assay may be employed and have a proven efficacy in cell culture models (Barriscale et al., 
2014). A luminescent reporter gene construct is prepared with the promoter region of interest 
cloned upstream of the luciferase gene; in this case it would include the regions where E2F-1 
may directly bind in the promoter region of the ncRNA. The expression vector is than transfected 
in the cells and after an incubation period the cells are lysed to extract the luciferase enzyme, to 
which bioluminescent protein Luciferin is added in conjunction with other reagents (Barriscale et 
al., 2014). The luciferin is broken down by the luciferase enzyme, and this is then measured by 
specialized apparatus which can illustrate the activity of the promoter region (Barriscale et al., 
2014). An ideal scenario for those candidate ncRNA that may be directly regulated E2F-1 
binding sites may fluoresce initially, and then lose this fluorescence if these E2F binding sites are 
disrupted. This would be indicative of direct influence of the pRB pathway. It is also intriguing 
to consider the other ncRNA that lack E2F-1 consensus sequences, perhaps their expression may 
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be regulated by other members of the pRB-dependent interactions and this avenue must be 
further explored. 
 
pRB Loss Promotes Misexpression of NcRNA  
The data presented above affirms the notion that pRB loss is associated with the 
misexpression of candidate ncRNAs. Unfortunately, there was a discrepancy or rather a failure to 
produce consistent pRB knockdown via a shRB approach. This may explain why different 
candidate ncRNAs were significantly upregulated in the siRB qPCR analysis than compared to 
shRB knockdown of pRB. In both experiments, the majority of the ncRNAs were upregulated 
but not significantly, perhaps significance could have been reached by preparing and analyzing 
addition replicates. Another important consideration is that the altered expression of these 
candidate ncRNA may be sensitive to levels of pRB loss, with siRB producing a stronger 
depletion of pRB than shRB approaches.  
Additionally, attempts were made to deduce whether or not the altered upregulation of 
ncRNAs may be specific to a specific phase of the cell cycle. These experiments made use of 
multiple cell synchronization approaches and DNA damaging reagents which were used to assess 
the sensitivity of ncRNA candidates to DNA damage, and to see at which point in the cell cycle 
these ncRNAs are misregulated following pRB loss. Further attempts could be made to explore 
ncRNA expression levels depending on the phase of the cell cycle. This may aid in devising 
future experiments, as different members of the pRB pathway are involved at different stages of 
the cell cycle. 
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pRB Deficient Cells Have Greater Motility Than Compared to Control Epithelial Cells 
 Alongside evidence for misexpression of candidate ncRNA, the potential implications of 
the upregulation were explored to further categorize the role of the candidate ncRNAs. Based on 
prior research, it appeared that one of the candidates BDNF-AS was implicated in having an 
inhibitory effect on cell proliferation and cell migration (Shang et al. (2018). This informed 
analysis of non-transformed RPE-1 cells in untreated control versus siRB knockdown of pRB 
conditions. Results from Figure 8 describe pRB depleted cells as having greater motility 
compared to control cells. These findings were consistent with what had been previously been 
described in tumor cell contexts, but our results were the first to demonstrate that pRB loss is 
sufficient to promote cell motility in a non-transformed human epithelial cell line. This altered 
motility could be verified by producing additional replicates or complementary assays. An 
intriguing experiment would be to attempt to deplete BDNF-AS to study the efficacy of this 
approach to reduce the motility of pRB deficient cells to levels seen in control cells. 
Clinical Significance 
 
pRB loss common in some human cancers is responsible for some of the hallmarks of 
cancer. When pRB is compromised many genes become dysregulated (as shown in Figure 4) 
which has many downstream effects on a cell, such as unregulated cell proliferation and altered 
motility and consequently flags numerous genes, as well as ncRNAs, that present different 
avenues for future therapies. One of the phenotypes explored was the motility of pRB deficient 
cells in non-transformed cells which is a novel approach. We posited that overexpression of 
certain ncRNAs could rescue the motility and restore it to control cells. The ncRNA we were 
interested in was BDNF-AS, which can be utilized as a dose-dependent novel therapeutic to treat 
pRB deficient cells. Most intriguing, however, is the evidence of the expression of ncRNAs may 
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be regulated by pRB-dependent mechanisms. Results showed that E2F-1 may bind directly to the 
promoter region of some ncRNAs, perhaps further analysis of these consensus sequences may 
provide future avenues for cancer therapeutics.  
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Methods 
Identification of ncRNA Candidates 
 RNA sequencing data produced by the Manning lab in 2015 was used to determine 
ncRNAs of interest. RNAseq was performed on siRNA KO of RB in RPE-1 cells and multiple 
gene-specific libraries were employed which produced data of misexpressed genes. This dataset 
was imported to Excel 2015, and using the filter tool, the results were filtered to show ncRNAs 
that were misexpressed.  Next, only those ncRNA with log2 fold change values of <-1 were 
sorted. A value of -1 means that in these siRNA treated cell lines, there is a 50% change in 
expression of a given gene than compared to an untreated cell line. Additionally, only those 
ncRNAs with p-value or significance of <0.001 were included in this initial analysis. This 
yielded a list of 10 ncRNA candidates. 
 
Maintenance of Cell Culture 
The adherent cell line human RPE-1 cells expressing a hTERT shRB were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM). This media contained 10% Fetal Bovine Serum 
(FBS) and 50ug/mL of streptomycin and penicillin.  
This cell line was subcultured at a ratio of 1:5 after 48 hours, where the media was 
aspirated out and the plate was washed with 2mL of 1X PBS which was also aspirated. Next, 2 
mL of trypsin was added to the cells and were left in an incubator for 5-6 minutes at 37oC. After 
incubation, 8 mL of fresh DMEM+10%FBS media was added to the plate. The cell suspension 
was then moved to a new 15 mL conical tube and was centrifuged for 5 minutes at 1000 rpm to 
pellet the cells and remove trypsin from the cells. The media was then aspirated out and 10 mL 
of fresh media was used to resuspend the cells. 2mL of this cell suspension was removed from 
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the 15 mL conical tube to a new 10cm cell culture dish, and the total volume was increased to 10 
mL with additional DMEM+10%FBS media. 
 
Knockdown of pRB 
This experiment was done in triplicates, and each time 2 plates were prepared using the 
protocol above. Throughout each replicate, one of the plates was treated with 2ug/mL of 
Doxycycline for 48 hours to induce knockdown at a ratio of 1:1000 of Doxycycline to total cell 
suspension volume.  
 
RNA Extraction and Purification 
Firstly the adherent human RPE-1 cells grown in a 10cm dish with a total volume of 
10mL were homogenized at room temperature. The DMEM+10%FBS media was aspirated and 
1mL of TRIzol reagent (Ambion) was added directly to the cells. The TRIzol aids in lysing the 
cells and lysis was ensured by pipetting up and down several times. Then approximately 1mL of 
lysed cells suspended in TRIzol were transferred to a 1.5mL eppendorf tube. Next a chloroform 
wash was performed to phase separate the sample. This step involved adding 0.2mL of 
chloroform was added and the tube was shaken vigorously for 15 seconds and was allowed to 
incubate at room temperature for 2 to 3 minutes. The sample was then centrifuged at 12000 x g 
for 15 minutes at 4oC. After centrifugation the sample phase separates due to the addition of 
chloroform. The tube then contains a lower red phenol-chloroform organic phase which contains 
protein, and interphase that contains DNA and a clear upper aqueous phase which contains the 
RNA. 0.5mL of the upper aqueous phase, which holds approximately 50% of the total volume of 
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the sample, was transferred to a fresh tube. The chloroform wash was repeated on the contents of 
fresh tube to extract to purify the RNA in the aqueous phase.  
Next 0.5mL of 100% isopropanol was added to the tubes to precipitate the RNA. The 
samples were incubated at room temperature for 10 minutes and then centrifuged at 12000 x g 
for 10 minutes at  4oC. This step yields a gel like pellet at the bottom-side of the tube. The 
supernatant was removed and the pellet was washed with 1mL of 75% ethanol. The tube was 
then vortexed briefly and then centrifuged at 7500 x g for 5 minutes at  4oC. After centrifugation, 
the supernatant was removed. This RNA wash step was repeated twice. 
Next the pellet was allowed to air dry for 5-10 minutes. After this step the RNA was 
resuspended in 25 µL of RNase free water. Finally the quality and quantity of the resuspend 
RNA was assessed via a NanoDrop spectrophotometer (Thermofisher). 
 
SYBR Green-based Quantitative real-time PCR (qrt-PCR) Protocol 
RNA was extracted via TRIzol (Ambion) using the protocol above. Complementary 
DNA was synthesized using ‘High-Capacity cDNA Reverse Transcription Kit with RNase 
Inhibitor’ (Applied Biosystems). To assess, the knockdown of pRB and verify the expression 
trends (generated from RNAseq analysis) of ncRNAs, quantitative real-time PCR was performed 
using SYBR green kit (Applied Biosystems). qPCR was done on 96 well plates which included 
GAPDH which acted as a control and gene specific primers for pRB and the ncRNA candidates. 
The cycle threshold was normalized to the cycle threshold for GAPDH. Three biological 
replicates were produced where each gene or ncRNA had two technical replicates within the 
plate. 
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The following gene-specific primers were used: 
 
Gene Gene type Forward Primer Reverse Primer 
ASAP1-IT1 
ncRNA TCCCTCCACAGAGTTTT
GCC 
ACCTCAGCTCCACGAAAA
CC 
KIRREL3-AS2 
ncRNA GTTCAAGGATGGCAGCA
GCAGG 
CCCCCGTTCTTGATTGGA
GT 
 
BDNF-AS 
ncRNA TTCGGGAATGTGGCTAA
GGG 
CGGACCATCTGTTCTGCT
GT 
LOC340113 
ncRNA CGAGACCTTTGGACCAA
GA 
ATGCTGTCTCTCTGACGCT
G 
RAD21-AS1 
ncRNA CAAAATGGTACCTGTGC
GCC 
 
CTTTGCGCTTGCTCAGTTG 
 
N4BP2L2-IT2 
ncRNA GCAAGCTTGATGAGGTC
CCA 
GACCAAGCAACAGTGAGC
AA 
 
 
LINC00342 
ncRNA CCACAGACTACCCAAAG
CAG 
 
TCACTCTGCTGCTTCAGA
AAAAT 
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PLCE1-AS1 
ncRNA CCCCTGATGTTTAACAC
AACGTT 
TGCTAACGTTCACCCAAG
TT 
 
CLSTN2-AS1 
ncRNA TGTTGCACAGGTCTCCT
CAC 
CCCCTGAGCCAACTCACT 
 
XIST 
ncRNA GACACAAGGCCAACGA
CCTA 
TCGCTTGGGTCCTCTATCC
A 
RB 
coding TGGTGAATCATTCGGGA
CTT 
GGTTTAGGAGGGTTGCTT
CC 
 
GAPDH 
coding CCCTCTGGTGGCCCCTT GGCGCCCAGACACCCAAT
CC 
Table 2: qPCR primer sequences. 
Preparation of Input Protein Samples for Western Blotting 
 One additional replicate of the shRB KO was prepared so that protein could be extracted 
from it. These protein samples would aid in western blot procedures to confirm the knockdown 
of pRB.  
 First the adherent human RPE-1 cells grown in a 10cm dish with a total volume of 10mL 
had their media was aspirated. This plate was then washed with 3 mL of PBS which was then 
aspirated. Next, 2 mL of trypsin was added to the cells and were left in an incubator for 5-6 
minutes at 37oC. After incubation, 8 mL of fresh DMEM+10%FBS media was added to the plate. 
The cell suspension was then moved to a new 15 mL conical tube and was centrifuged for 5 
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minutes at 1000 rpm to pellet the cells and remove trypsin from the cells. The media was then 
aspirated out and 10 mL of fresh media was used to resuspend the cells.  
 Then 10µL of media was drawn from this 10mL conical. The 10µL was pipetted onto a 
hemocytometer which was used to count the cells. The volume to get 1x107 cells was determined 
and this volume of cells was added to a 1.5mL eppendorf tube. Next the sample in the eppendorf 
was resuspended in 3 times the calculated volume in 2X Laemmli buffer (Biorad). The 1.5mL 
eppendorf tubes were then transferred to a heat block set at 95oC for 2 minutes; the boiling 
ensured degradation of protein by denaturing proteases that may be present in the sample. 
Finally, these samples were stored at -20oC. 
 
pRB Knockout via siRB 
 The siRNA knockout experiments were previously performed by members of the 
Manning lab. These knockout experiments were performed in triplicates but gene expression 
levels of candidate ncRNAs were not studied. To further verify the expression trends seen in the 
shRB knockdown and RNAseq analysis, previously stored RNA (at -80°C) was used to 
synthesize cDNA which was used to perform qPCR for the 10 ncRNA candidates in triplicate. 
 
Cell synchronization and Knockdown of pRB Experimental setup 
First the adherent human RPE-1 cells grown in a 10cm dish with a total volume of 10mL 
had their media was aspirated. This plate was then washed with 3 mL of PBS which was then 
aspirated. Next, 2 mL of trypsin was added to the cells and were left in an incubator for 5-6 
minutes at 37oC. After incubation, 8 mL of fresh DMEM+10%FBS media was added to the 
plate. The cell suspension was then moved to a new 15 mL conical tube and was centrifuged for 
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5 minutes at 1000 rpm to pellet the cells and remove trypsin from the cells. The media was then 
aspirated out and 10 mL of fresh media was used to resuspend the cells. Then 10µL of media 
was drawn from this 10mL conical. The 10µL was pipetted onto a hemocytometer which was 
used to count the cells. A volume equivalent to 7.5 x 104 cells was plated on a 6 well dish and the 
total volume was increased with fresh DMEM+10%FBS media to 2mL.  
 
Addition of small molecules 
This experiment made use of the mitotic inhibiting drugs including Nocodazole (Sigma-
Aldrich) at 100 ng/mL and Aphidicolin (Abcam) at 4µM. The DNA damaging reagent 
Hydroxyurea (Sigma-Aldrich) was used at 2mM. These reagents were resuspended in DMSO. 
Three replicates were performed, each replicate of this experiment involved preparing 
two 6-well dishes where 4 wells of of the dish had 7.5 x 104 cells plated. One of the dishes had 
2ug/mL of Doxycycline added to them to induce knockdown (at a ratio of 1:1000). The 2 plates 
were allowed to grow for 48 hours. After 48 hours the plates were treated with small molecules 
except for the control well, and were kept in drug for 16 hours. It is important to note that each 
plate included wells for: a control (no addition of small molecule), Nocodazole, Aphidicolin and 
Hydroxyurea.  
 
RNA Extraction, cDNA Synthesis and qPCR from 6 well dish 
 After a 16 hours, RNA was extracted from the 6 well plates. Firstly the adherent human 
RPE-1 cells grown in the 6 well dishes with a total volume of 2mL  per well were homogenized 
at room temperature. Then the DMEM+10%FBS media was aspirated from the dish. A PBS 
wash was performed and the added PBS was aspirated as well. Next, 250uL of TRIzol (ambion) 
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reagent directly to the cells to collect. Then approximately ~250uL of lysed cells suspended in 
TRIzol was transferred to a 1.5mL eppendorf tube. Next a chloroform wash to phase separate the 
sample was performed. This step involves adding 50uL of chloroform to the tube which is to be 
shaken vigorously for 15 seconds and was allowed to incubate at room temperature for 2 to 3 
minutes. The samples were then centrifuged at 12000 x g for 15 minutes at 4oC. After 
centrifugation the sample phase separates due to the addition of chloroform. ~125uL of the upper 
aqueous phase should be transferred to a fresh tube. The chloroform wash was repeated once 
more, but with 2µL of chloroform. Then transfer ~125µL of aqueous phase to fresh tubes. After 
this step, 0.5uL of glycol blue was added to aid in visualizing pelleted RNA at later steps. Next, 
100% isopropanol was added to the tubes, at a volume 5 fold of what the volume of the aquesous 
phase that was collected. The samples were incubated Isopropanol and glycol blue at room 
temperature for 10 minutes and then centrifuged at 12000 x g for 10 minutes at  4oC. A pellet was 
visualized and the supernatant was removed. An ethanol wash with 1mL of 75% ethanol and 
centrifugation at 7500 x g for 5 minutes at  4oC was performed. After centrifugation the 
supernatant was removed, and the ethanol wash was repeated once more. Once the supernatant 
was removed, the pelleted RNA was air dried for 5-10 minutes. Finally the pellet was 
resuspended in 20 µL of RNase free water and the quality and yield were assessed via the 
NanoDrop spectrophotometer (Thermofisher).cDNA and qPCR was performed in accordance 
with ‘SYBR Green-based Quantitative real-time PCR (qrt-PCR) Protocol.’ 
 
Determining Putative E2F Binding Sites 
 E2F consensus sequences were extracted from by the University of California, Irvine’s 
free online tool called MotifMap. This database contains a comprehensive genome-wide map of 
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regulatory elements which includes transcription factor consensus sequences. Out of 21 entries 
only 2 were enriched in the promoter region of the candidate ncRNAs; HNTTTCHN (Human, 
E2F-1 consensus sequence) and VRAAAHST (Human, E2F-1 consensus sequence). In order to 
align these E2F-1 consensus sequence in the promoter region of ncRNA, two different promoter 
region servers were used to determine the transcriptional start sites (TSS). The first tool used was 
University of California Santa Cruz’s genome browser tool. The candidate ncRNA were 
searched for, and the genomic DNA sequence was extracted. This website also has a variety of 
checkboxes so that only the annotated promoter region can be exported. In order to confirm the 
TSS and promoter region, the whole genomic DNA sequence was inputted in the Technical 
University of Denmark’s online promoter prediction server. This powerful tool leverages 
complex algorithms to simulate binding of transcription factor interactions in the promoter 
region of the inputted sequence and gives a statistical prediction of a likely TSS. Once the TSS 
was determined the Broad Institute’s Integrative Genomics Viewer software was used to align 
the consensus sequences in the promoter region of the ncRNAs. Specifically, the motif finder 
tool was used, where the consensus sequences were inputted to generate hits illustrated in Figure 
7. 
 
Cell Motility Assay 
 This experiment involved analyzing the 2-dimensional motility of control and pRB 
deficient cells using movies that were generated by a previous student in the Manning Lab. The 
previous student made use of an hTERT RPE-1 cell line. This cell line was constructed so that it 
was able to express red fluorescent protein tagging histone 2B (RFP-H2B). This allowed for the 
nuclei to be visualized which aided in the analysis of the cells using the Cell Profiler software 
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suite. The previous student maintained and subcultured the cells using a similar protocol as noted 
above. Microscopic images were collected every 5 minutes for up to 36 hours. 
 In order to track the motility of the cells, the Cell Profiler Software parameters had to be 
optimized to track the cells properly. Firstly, I downloaded a default ‘Object Tracking and 
Metadata Management’ pipeline. This pipeline or series of functions was set up to track multiple 
objects (cells in this case) and several sequences of images in a time-lapse experiment and is 
optimized to track moving cells from frame to frame, which is a challenging task. The first step 
was to drag and drop this pipeline onto the sotware which then automatically loads the various 
functions in the pipeline. Next the images are dragged and dropped into the software. It is at this 
point that a naming convention must be established, so that the software is able to extract the 
metadata of the images including: 1) the well ID, 2) frame number and 3) timepoint or frame 
number. Cell Profiler is capable of extracting the metadata automatically (Figure 9), but 
sometimes the software is unable to detect it thus the formula: ^(?P<Well>.*)_ 
(?P<Treatment>.*)_ 1T(?P<timepoint>[0-9]*) must be used. To further breakdown this formula, 
the function ‘?P’ tells the software to begin to search the title for or string which is enclosed in ‘< 
>.’ Finally we must inform the software of what the numeric range is which is denoted by giving 
a range of values enclose in ‘[].’  
 
Figure 9: Screenshot of cell profiler software metadata tab. 
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A)  
B)  
Figure 10: Screenshot of cell profiler software. A) NamesAndTypes module and B) Color to 
Gray module. 
Subsequently, the software must be told what to label the images for analysis (Figure 10A), since 
this analysis is looking at nuclei of cells the name assigned was ‘DNA.’ This is important as we 
need to refer to these batch of images in order to convert them to grayscale, which is essential 
when assessing the morphology of cells as grayscale allows for just accounting for intensity of 
signal rather than intensity of a colored channel for example. Figure 10B shows the settings used, 
The output images were called ‘DNAGrayScale.’ 
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Figure 11: Screenshot of Cell Profiler Software IdentifyPrimaryObjects module. 
Unfortunately, the default pipeline was having trouble tracking all the cells in a frame of view 
due to differential fluorescent intensity. Thus, the parameters were adjusted as seen in Figure 11. 
The most important variable to adjust was threshold smoothing scale as well as correction factor. 
These values could be the difference from the software perceiving two cells close to each other 
as one or 2 distinct cells. The thresholding method was also important; this analysis made use of 
the Otsu method which involves producing a histogram of the spread of the intensity of 
individual pixels of the cell and is able to more distinctly tell two cells apart as this algorithm is 
able to reduce the signal of the intensity in ways that are beyond the scope of this project 
(Dongju Liu, 2009). The software also had to be instructed as two what is a typical range of 
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diameter of the cells. This was a rudimentary task, as the raw images were opened in the 
software and using the ruler function the diameter was measured for around 10 cells to 
appreciate the range of diameters of cells. The measurements made by this module include a 
count of the objects tracked as well as the xy coordinates of each of the identified cells. 
 
Figure 12: Screenshot of Cell Profiler Software TrackObjects module. 
This function was instrumental in the analysis of the motility of the cell. The module 
outputted the displacement which is the shortest distance traveled by the object between two 
points. Perhaps most importantly, this module kept track of the labeled objects. This is an 
important point which complicated the motility analysis. The module from Figure 11 outputs the 
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number of objects tracked, but for example, if a cell leaves the field of view and comes back, it is 
perceived as a new object. This is in contrast to the label output which uniquely identifies a cell 
in the lifetime of the movie. For our analysis we looked at a totally of 100 cells that were labeled 
and could be tracked for a minimum of 12 frames or an hour. 
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